NASDAQ:AGIO

Agios Pharmaceuticals Competitors

$54.24

+2.18 (+4.19 %)

(As of 04/14/2021 11:51 AM ET)

Add

Compare

Today's Range

$53.37

Now: $54.24▼

$54.80

50-Day Range

$46.10

MA: $50.56▼

$54.83

52-Week Range

$32.47

Now: $54.24▼

$58.93

Volume9,784 shs

Average Volume775,221 shs

Market Capitalization$3.78 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.8

Agios Pharmaceuticals (NASDAQ:AGIO) Vs. ZLAB, BMRN, ELAN, GRFS, TEVA, and BHC

Should you be buying AGIO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Agios Pharmaceuticals, including Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), and Bausch Health Companies (BHC).

Agios Pharmaceuticals vs. Zai Lab Stock

Zai Lab (NASDAQ:ZLAB) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Zai Lab and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$12.98 million	1,133.81	$-195,070,000.00	($3.03)	-54.83
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

Zai Lab has higher earnings, but lower revenue than Agios Pharmaceuticals. Zai Lab is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Zai Lab and Agios Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0	0	5	0	3.00
Agios Pharmaceuticals	0	3	7	0	2.70

Zai Lab presently has a consensus price target of $197.8460, suggesting a potential upside of 20.01%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.97%. Given Zai Lab's stronger consensus rating and higher probable upside, research analysts plainly believe Zai Lab is more favorable than Agios Pharmaceuticals.

Volatility & Risk

Zai Lab has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Zai Lab and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zai Lab	N/A	N/A	N/A
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Institutional & Insider Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Zai Lab beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals vs. BioMarin Pharmaceutical Stock

BioMarin Pharmaceutical (NASDAQ:BMRN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$1.70 billion	8.38	$-23,850,000.00	$0.07	1,122.57
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

BioMarin Pharmaceutical has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for BioMarin Pharmaceutical and Agios Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0	8	11	0	2.58
Agios Pharmaceuticals	0	3	7	0	2.70

BioMarin Pharmaceutical presently has a consensus price target of $117.50, suggesting a potential upside of 49.24%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.97%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than Agios Pharmaceuticals.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares BioMarin Pharmaceutical and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	45.74%	4.34%	2.84%
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Institutional & Insider Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Agios Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals vs. Elanco Animal Health Stock

Elanco Animal Health (NYSE:ELAN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Elanco Animal Health and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$3.07 billion	4.58	$67.90 million	$1.06	28.05
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

Elanco Animal Health has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Elanco Animal Health and Agios Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	2	3	6	0	2.36
Agios Pharmaceuticals	0	3	7	0	2.70

Elanco Animal Health presently has a consensus price target of $31.35, suggesting a potential upside of 5.20%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.97%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Elanco Animal Health.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-8.45%	3.43%	2.04%
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Agios Pharmaceuticals beats Elanco Animal Health on 8 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals vs. Grifols Stock

Grifols (NASDAQ:GRFS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Grifols and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grifols	12.79%	10.65%	4.79%
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Volatility & Risk

Grifols has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.

Earnings and Valuation

This table compares Grifols and Agios Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$5.71 billion	2.15	$700.16 million	$1.17	15.25
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

Grifols has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.2% of Grifols shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Grifols and Agios Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0	2	5	0	2.71
Agios Pharmaceuticals	0	3	7	0	2.70

Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 18.97%. Given Agios Pharmaceuticals' higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Grifols.

Summary

Grifols beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals vs. Teva Pharmaceutical Industries Stock

Teva Pharmaceutical Industries (NYSE:TEVA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares Teva Pharmaceutical Industries and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	-24.17%	19.32%	4.89%
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Valuation & Earnings

This table compares Teva Pharmaceutical Industries and Agios Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$16.89 billion	0.72	$-998,000,000.00	$2.31	4.80
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

Agios Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Teva Pharmaceutical Industries and Agios Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1	9	4	0	2.21
Agios Pharmaceuticals	0	3	7	0	2.70

Teva Pharmaceutical Industries presently has a consensus target price of $11.80, suggesting a potential upside of 6.79%. Agios Pharmaceuticals has a consensus target price of $64.6364, suggesting a potential upside of 18.97%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Summary

Agios Pharmaceuticals beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals vs. Bausch Health Companies Stock

Bausch Health Companies (NYSE:BHC) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Insider and Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bausch Health Companies and Agios Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	1	4	7	0	2.50
Agios Pharmaceuticals	0	3	7	0	2.70

Bausch Health Companies presently has a consensus target price of $32.5833, suggesting a potential upside of 7.11%. Agios Pharmaceuticals has a consensus target price of $64.6364, suggesting a potential upside of 18.97%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Bausch Health Companies.

Risk & Volatility

Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Bausch Health Companies and Agios Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-23.92%	173.20%	4.21%
Agios Pharmaceuticals	-170.65%	-57.63%	-37.15%

Valuation & Earnings

This table compares Bausch Health Companies and Agios Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	$8.60 billion	1.26	$-1,788,000,000.00	$4.43	6.88
Agios Pharmaceuticals	$117.91 million	32.02	$-411,470,000.00	($6.86)	-7.91

Agios Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Bausch Health Companies beats Agios Pharmaceuticals on 7 of the 13 factors compared between the two stocks.